← Back to Search

Augmented Reality Game for Pediatric Cancer

Phase 2
Waitlist Available
Led By Juan Cata, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through completion of study, an average of 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing if a game can help young patients reduce pain and the need for opioids before surgery.

Who is the study for?
This trial is for children aged 5-15 with cancer, scheduled for major surgery requiring at least one night's hospital stay. They must be opioid-naïve, able to understand and interact with an iPad game, and have parents/guardians who can consent. Children over 15 or those with prior neuropathy or recent opioid use are excluded.
What is being tested?
The study tests if a SpellBound augmented reality game on an iPad can help reduce pain and lessen the need for opioids in pediatric patients after surgery. It's a randomized controlled trial comparing game interaction outcomes against standard postoperative care.
What are the potential side effects?
Since this intervention involves playing an augmented reality game rather than medication, typical drug side effects aren't expected. However, there may be non-medical concerns such as eye strain or frustration if difficulty using the app occurs.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through completion of study, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through completion of study, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Pediatric Quality of Life Inventory Questionnaires

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Group 2 (Spellbound)Experimental Treatment1 Intervention
Participants will play the game using augmented reality
Group II: Group 1(Spellbound)Experimental Treatment1 Intervention
Participants will play the game using the iPad's standard camera, which will show you your hospital room and the decals as they appear in the real world.

Find a Location

Who is running the clinical trial?

National Institutes of Health (NIH)NIH
2,826 Previous Clinical Trials
8,169,597 Total Patients Enrolled
M.D. Anderson Cancer CenterLead Sponsor
3,070 Previous Clinical Trials
1,802,798 Total Patients Enrolled
Juan Cata, MDPrincipal InvestigatorM.D. Anderson Cancer Center
5 Previous Clinical Trials
171 Total Patients Enrolled

Media Library

Group 1(Spellbound) Clinical Trial Eligibility Overview. Trial Name: NCT05466994 — Phase 2
Acute Lymphoblastic Leukemia Research Study Groups: Group 1(Spellbound), Group 2 (Spellbound)
Acute Lymphoblastic Leukemia Clinical Trial 2023: Group 1(Spellbound) Highlights & Side Effects. Trial Name: NCT05466994 — Phase 2
Group 1(Spellbound) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05466994 — Phase 2
~13 spots leftby Oct 2026